Alexion Pharmaceuticals News

Alexion Pharmaceuticals, Inc. today announced that Vikas Sinha, Chief Financial Officer of Alexion Pharmaceuticals, will present at the Deutsche Bank 38th Annual dbAccess Health Care Conference in Boston at 3:30 p.m. Eastern time on Thursday, May 30, 2013.

's stock had its "outperform" rating restated by Zacks in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Alexion Pharmaceuticals, Inc.

Below are the three companies in the Biotechnology industry with the highest free cash flow per share.

Shares of Alexion Pharmaceuticals traded down 1.65% during mid-day trading on Tuesday, hitting $97.03. Alexion Pharmaceuticals has a one year low of $81.28 and a one year high of $119.54. The stock's 50-day moving average is currently $94.42. The company has a market cap of $18.899 billion and a P/E ratio of 67.71. Alexion Pharmaceuticals last ... (more)

Since our last report on Alexion Pharmaceuticals on April 5, shares have remained flat as continued concerns about the company's manufacturing facilities and Soliris' market expansion have weighed down the stock price.

The firm currently has a "buy" rating on the stock. Alexion Pharmaceuticals opened at 99.34 on Friday.

Alexion Pharmaceuticals updated its FY13 earnings guidance on Thursday. The company provided earnings per share guidance of $2.87-2.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86, Analyst Ratings.Net reports.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. today announced that it is broadening and strengthening its executive leadership team in line with the Company's expanding global mission to develop and commercialize life transforming therapies for patients with disorders that are severe, life-threatening, and ultra-rare. Stephen Squinto, Ph.D., co-founder of Alexion, ... (more)